

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Christensen et al. Confirmation No: To be assigned
Serial No.: To be assigned Group Art Unit: To be assigned
Filed: March 15, 2002 Examiner: To be assigned
For: Methods for Producing Polypeptides In Aspergillus Mutant Cells



INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references was filed in US application no. 09/472,364 filed December 23, 1999, the benefit of which is claimed under 35 USC 120.

The references are as follows:

1. SU 1271068
2. WO 95/15391
3. WO 95/15390
4. Abstract of Russian Patent No. SU 1271068
5. Abstract of Article: Tudzynski et al., Mol. Gen. Genet. Vol. 261, pp. 133-141 (1999)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,

Date: March 15, 2002

A handwritten signature in dark ink, appearing to read "Elias J. Lambiris", is written over a horizontal line.

Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant
Christensen et al.

Filing Date
March 15, 2002

Group	To be assigned
-------	----------------

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

[illegible]

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.